| Title |
Emerging therapeutic options for sporadic inclusion body myositis
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, September 2015
|
| DOI | 10.2147/tcrm.s65368 |
| Pubmed ID | |
| Authors |
Lindsay N Alfano, Linda P Lowes |
| Abstract |
Sporadic inclusion body myositis is the most common inflammatory muscle disorder preferentially affecting males over the age of 40 years. Progressive muscle weakness of the finger flexors and quadriceps muscles results in loss of independence with activities of daily living and eventual wheelchair dependence. Initial signs of disease are often overlooked and can lead to mis- or delayed diagnosis. The underlying cause of disease is unknown, and disease progression appears refractory to available treatment options. This review discusses the clinical presentation of inclusion body myositis and the current efforts in diagnosis, and focuses on the current state of research for both nonpharmacological and pharmacological treatment options for this patient group. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 33 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 21% |
| Student > Master | 5 | 15% |
| Student > Ph. D. Student | 4 | 12% |
| Student > Bachelor | 3 | 9% |
| Other | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 7 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 30% |
| Nursing and Health Professions | 4 | 12% |
| Neuroscience | 3 | 9% |
| Psychology | 2 | 6% |
| Sports and Recreations | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 10 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2015.
All research outputs
#16,188,873
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#729
of 1,308 outputs
Outputs of similar age
#147,770
of 277,177 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#34
of 62 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,177 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.